Evidence map›Paper›PMID 40487580›Full record

ArticleNeuro-oncology practice2025

Risk factors for type I leptomeningeal metastasis derived from non-small cell lung cancer and the impact of treatment for brain metastases on its development.

Toshihiko Iuchi, Masato Shingyoji, Satoko Mizuno, Hironori Ashinuma, Yuzo Hasegawa, Taiki Setoguchi, Junji Hosono, Tsukasa Sakaida

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Toshihiko IuchiDivision of Neurological Surgery, Chiba Cancer Center, Chiba, Japan.ORCID https://orcid.org/0000-0002-4933-0049
Masato ShingyojiDivision of Respirology, Chiba Cancer Center, Chiba, Japan.
Satoko MizunoDivision of Respirology, Chiba Cancer Center, Chiba, Japan.
Hironori AshinumaDivision of Respirology, Chiba Cancer Center, Chiba, Japan.
Yuzo HasegawaDivision of Neurological Surgery, Chiba Cancer Center, Chiba, Japan.
Taiki SetoguchiDivision of Neurological Surgery, Chiba Cancer Center, Chiba, Japan.
Junji HosonoDivision of Neurological Surgery, Chiba Cancer Center, Chiba, Japan.
Tsukasa SakaidaDivision of Neurological Surgery, Chiba Cancer Center, Chiba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Preventing Type I leptomeningeal metastasis (LM) is critical when treating brain metastases (BMs). The aim of this study was to extract risk factors for Type I LM and to clarify the optimal treatment for BMs from the perspective of Type I LM prevention. Methods: The clinical course of consecutive cases of BMs derived from non-small cell lung cancer (NSCLC) treated at our hospital was retrospectively evaluated. The relationship between clinicopathological factors, including molecular background, and Type I LM development was verified. In addition, the difference in the time to Type I LM because of treatment for BMs was evaluated to clarify the effectiveness of each treatment in preventing Type I LM. Results: Of 784 patients with BMs, 44 exhibited Type I LM at the onset of BMs. Poor performance status ( Conclusions: Patients with

Indexed as

EGFRimmune checkpoint inhibitorleptomeningeal metastasisnon-small cell lung cancertyrosine kinase inhibitor

Identifiers

PMID40487580
PMCPMC12137222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.